Open AccessPrevalence and Treatment of Osteoporosis Prior to Elective Shoulder Arthroplasty
Author(s) -
James T. Bernatz,
Andrew E. Brooks,
Benjamin P. Nguyen,
Edward D Shin,
Neil Binkley,
Paul A. Anderson,
Brian F. Grogan
Publication year - 2020
Publication title -
journal of the american academy of orthopaedic surgeons. global research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.358
H-Index - 2
ISSN - 2474-7661
DOI - 10.5435/jaaosglobal-d-20-00204
Subject(s) - medicine , osteoporosis , arthroplasty , medical prescription , retrospective cohort study , surgery , physical therapy , pharmacology
Introduction: The rate of preoperative osteoporosis in lower extremity arthroplasty is 33%. The prevalence of osteoporosis in shoulder arthroplasty patients is inadequately studied. The purpose of this study was to (1) determine the prevalence of osteoporosis in patients undergoing elective shoulder arthroplasty, (2) report the percentage of patients having dual-energy x-ray absorptiometry (DEXA) testing before surgery, and (3) determine the percentage of patients who have been prescribed osteoporosis medications within 6 months before or after surgery. Methods: This retrospective case series included all adults aged 50 years and older who underwent elective shoulder arthroplasty at a single tertiary care center over an 8-year period. National Osteoporosis Foundation (NOF) criteria for screening and treatment were applied. Results: Two hundred fifty-one patients met the inclusion criteria; 171 (68%) met the criteria for DEXA testing, but only 31 (12%) had this testing within 2 years preoperatively. Eighty patients (32%) met the NOF criteria for receipt of pharmacologic osteoporosis treatment, and 17/80 (21%) received a prescription for pharmacotherapy. Discussion: Two-thirds of elective shoulder arthroplasty patients meet the criteria to have bone mineral density measurement done, but less than 20% have this done. One in three elective shoulder arthroplasty patients meet the criteria to receive osteoporosis medications, but only 20% of these patients receive therapy.